Astrana Health, Inc. (ASTH)
(Delayed Data from NSDQ)
$48.12 USD
+0.19 (0.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.67 +0.55 (1.14%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.12 USD
+0.19 (0.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.67 +0.55 (1.14%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Zacks News
Astrana Health, Inc. (ASTH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of 5.26% and 9.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OPCH vs. ASTH: Which Stock Is the Better Value Option?
by Zacks Equity Research
OPCH vs. ASTH: Which Stock Is the Better Value Option?
Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Astrana Health, Inc. (ASTH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Astrana Health, Inc. (ASTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.20% and 2.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here is Why Growth Investors Should Buy Astrana Health, Inc. (ASTH) Now
by Zacks Equity Research
Astrana Health, Inc. (ASTH) possesses solid growth attributes, which could help it handily outperform the market.
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 21.43% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 18.18% and 4.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health Inc. (ASTH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Astrana Health Inc. (ASTH) delivered earnings and revenue surprises of 52.94% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?